Frankfurt
20.08.26 | 08:00
0,014 Euro
-1,42 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Acarix AB Q2 Sales Increase | 10 | RTTNews | ||
| 13.08. | Earnings Call: Acarix meldet starkes Wachstum für Q2 2026, doch die Aktie gibt nach | 10 | Investing.com Deutsch | ||
| 13.08. | Acarix Q2 2026 slides: US revenue surges 212%, losses narrow | 5 | Investing.com | ||
| 13.08. | Acarix Q2 2026 slides: revenue doubles as US growth accelerates | 1 | Investing.com | ||
| ACARIX Aktie jetzt für 0€ handeln | |||||
| 13.08. | Acarix AB: Acarix Publishes Second Quarter and First Half 2026 Results | 131 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its interim financial results for the second quarter and first half 2026. The report highlights continued commercial... ► Artikel lesen | |
| 17.06. | Acarix AB: Announcement from the annual general meeting in Acarix AB | 273 | GlobeNewswire (Europe) | The annual general meeting 2026 (the "AGM") of Acarix AB ("Acarix" or the "Company") was held today on 17 June 2026 and the following resolutions were passed by the meeting.
Adoption of the income statement... ► Artikel lesen | |
| 18.05. | Earnings Call: Acarix verzeichnet starkes US-Wachstum im ersten Quartal 2026 | 2 | Investing.com Deutsch | ||
| 18.05. | Acarix AB: Acarix Publishes Interim Report, January - March 2026 | 281 | GlobeNewswire (Europe) | Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its interim financial results for the first quarter of 2026. The report highlights meaningful progress across the... ► Artikel lesen | |
| 12.02. | Acarix AB: Acarix Publishes Year-End Report 2025 | 280 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today reported its 2025 year-end financial results. "Last year was a year of meaningful commercial and operational... ► Artikel lesen | |
| 11.02. | Acarix AB: Acarix Announces New Distribution Partner in Saudi Arabia for the CADScor System | 434 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix AB (Nasdaq Stockholm: ACARIX), a medical device company advancing noninvasive, AI enabled diagnostics for coronary artery disease, today announced that it has entered into a strategic... ► Artikel lesen | |
| 04.02. | Acarix AB: Acarix Receives EU MDR Certification for the CADScorSystem | 382 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announced that its CADScor System has successfully achieved certification under the European Union Medical... ► Artikel lesen | |
| 06.11.25 | Acarix AB: Acarix Publishes Interim Report, Third quarter 2025 | 271 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the third quarter of 2025. The report highlights international... ► Artikel lesen | |
| 27.10.25 | Acarix AB: Announcement from the general meeting in Acarix AB | 325 | GlobeNewswire (Europe) | The extraordinary general meeting 2025 (the "EGM") of Acarix AB ("Acarix" or the "Company") was held today on 27 October 2025 and the following resolutions were passed unanimously by the meeting.
Change... ► Artikel lesen | |
| 17.10.25 | Acarix AB: Acarix responds to G-BA decision on reimbursement in the German market | 367 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that G-BA reached a negative decision on the possibility for CADScor System to receive reimbursement... ► Artikel lesen | |
| 21.08.25 | Acarix AB: Acarix Reports Significant Progress Toward Fixed Reimbursement | 319 | GlobeNewswire (Europe) | Malmö, Sweden - Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another milestone on its path toward fixed reimbursement... ► Artikel lesen | |
| 21.08.25 | Acarix AB: Acarix Publishes Interim Report, January - June 2025 | 314 | GlobeNewswire (Europe) | Malmö, Sweden (Aug. 21, 2025) - Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the second quarter and first half of 2025. The... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 40,890 | -0,10 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,140 | -0,31 % | Milliardenmarkt Augengesundheit: Warum EssilorLuxottica und Carl Zeiss Meditec auf neue Technologien setzen - und wo Rise Nano Optics ins Spiel kommt | ||
| ECKERT & ZIEGLER | 13,480 | +0,52 % | Eckert & Ziegler: Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ... | Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license income... ► Artikel lesen | |
| UNITEDHEALTH | 329,80 | +0,06 % | UnitedHealth nach Margin-Erholung: Ist das Wachstum schon ausgereizt? | UnitedHealth hat die Margenerholung im Kerngeschäft weitgehend eingepreist, doch das Bewertungsniveau signalisiert, dass die nächste Bewährungsprobe im Wachstum liegt. Angesichts eines Kursanstiegs... ► Artikel lesen | |
| HIMS & HERS HEALTH | 27,800 | +1,91 % | Barclays senkt Kursziel für Hims and Hers wegen Margendrucks | ||
| BICO GROUP | 1,734 | -0,12 % | BICO Group AB: Publication of BICO Group AB: Interim Report Q2 2026 | Improved profitability and AI advancements
"In the quarter we had a continued solid momentum with growth in our bench top instruments and consumables businesses, while still experiencing challenges... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | XFRA 79O: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUGEN MEDICAL DEV.... ► Artikel lesen | |
| SPINEWAY | 0,118 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,060 | +1,69 % | UniDoc Health Corp.: UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform | Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| VERU | 2,590 | +0,39 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| VIROMED MEDICAL | 7,050 | -2,08 % | Viromed Medical AG bricht ein - was Anleger wissen müssen | ||
| CLARIANE | 4,016 | 0,00 % | Clariane: First-half 2026 results | Half-Year Results: strong improvement in operating performanceSuccessful refinancing transactions Objectives confirmed Strong improvement in operating performance Revenue as at 30 June 2026 stood... ► Artikel lesen | |
| BONESUPPORT | 20,380 | -0,10 % | Bonesupport Holding AB: BONESUPPORT HOLDING AB (publ) - publishes Q2 2026 interim report | BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the second quarter 2026.
"Strong growth and improved operating... ► Artikel lesen | |
| SENSEONICS | 7,650 | +1,32 % | Senseonics sees activist investor take a major stake |
ACARIX AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,014 Euro und damit -1,42 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACARIX AB finden Sie auf Wallstreet Online.